Aktie A069620 DAEWOONG PHARMACEUTICAL CO., LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Daewoong Pharmaceutical Co., Ltd

Aktien

A069620

KR7069620003

A069620

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 14.05.2024 		% 5 Tage % 1. Jan.
111 500 KRW +1,64 % Intraday Chart für Daewoong Pharmaceutical Co., Ltd -0,80 % -4,54 %
24.04. Koreanische Zuckerimporte brechen um 14% ein, da Diabetesfälle zunehmen MT
15.02. Daewoong Pharmaceutical erhält Genehmigung für Stammzellenverarbeitungsanlage in Indonesien MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge
AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia
Daewoong Pharmaceutical : and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S.
Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., Ltd. Announces Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S
Daewoong Pharmaceutical : Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy
P.T. Selatox Bio Pharma announced that it expects to receive IDR 200 billion in funding from Daewoong Pharmaceutical Co., Ltd
Daewoong Pharmaceutical : announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia
Hyphens Pharma International Limited Announces Successful Registration in Malaysia
Daewoong Pharmaceutical : Initiates Global Export of 'Novel Drug'...Launches 'Fexuprazan' in the Philippines
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Daewoong Pharmaceutical's Nabota Surpasses 600,000 Customers in the US
Daewoong Pharmaceutical : Reports Second Quarter 2023 Financial Results
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A069620 Aktie
  4. Nachrichten Daewoong Pharmaceutical Co., Ltd
  5. Andere Sprachen